Literature DB >> 27696517

CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?

Francesco Zaja1, Valentina Tabanelli2, Claudio Agostinelli3,4, Angelica Calleri2, Annalisa Chiappella5, Marzia Varettoni6, Pier Luigi Zinzani7, Stefano Volpetti1, Elena Sabattini3, Renato Fanin1, Stefano A Pileri2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27696517     DOI： 10.1002/ajh.24571

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  13 in total

Review 1.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 2.  Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.

Authors:  Lorenzo Falchi
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

3.  Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas.

Authors:  Carlos A Murga-Zamalloa; Noah A Brown; Ryan A Wilcox
Journal:  J Clin Pathol       Date:  2019-10-31       Impact factor: 3.411

Review 4.  Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.

Authors:  Heliang Li; Phei Er Saw; Erwei Song
Journal:  Cell Mol Immunol       Date:  2020-04-20       Impact factor: 11.530

5.  Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features.

Authors:  Rebeca Manso; Julia González-Rincón; Manuel Rodríguez-Justo; Giovanna Roncador; Sagrario Gómez; Margarita Sánchez-Beato; Miguel A Piris; Socorro M Rodríguez-Pinilla
Journal:  Oncotarget       Date:  2018-03-01

Review 6.  Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.

Authors:  Thomas G Martin; Kathryn Corzo; Marielle Chiron; Helgi van de Velde; Giovanni Abbadessa; Frank Campana; Malini Solanki; Robin Meng; Helen Lee; Dmitri Wiederschain; Chen Zhu; Alexey Rak; Kenneth C Anderson
Journal:  Cells       Date:  2019-11-26       Impact factor: 6.600

Review 7.  Novel targeted therapies of T cell lymphomas.

Authors:  Katarzyna Iżykowska; Karolina Rassek; Dorota Korsak; Grzegorz K Przybylski
Journal:  J Hematol Oncol       Date:  2020-12-31       Impact factor: 17.388

8.  BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified.

Authors:  Mario L Marques-Piubelli; Luisa M Solis; Francisco Vega; Paolo Strati; Edwin R Parra; Luis Malpica Castillo; Sushanth Gouni; Ranjit Nair; Dai Chihara; Marina Konopleva; Ignacio I Wistuba; Swaminathan P Iyer
Journal:  Blood Cancer J       Date:  2021-09-16       Impact factor: 11.037

9.  Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.

Authors:  Laura Ballotta; Pier Luigi Zinzani; Stefano Pileri; Riccardo Bruna; Monica Tani; Beatrice Casadei; Valentina Tabanelli; Stefano Volpetti; Stefano Luminari; Paolo Corradini; Elisa Lucchini; Maria Chiara Tisi; Michele Merli; Alessandro Re; Marzia Varettoni; Emanuela Anna Pesce; Francesco Zaja
Journal:  Front Oncol       Date:  2021-12-06       Impact factor: 6.244

Review 10.  The Many Facets of CD38 in Lymphoma: From Tumor-Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy.

Authors:  Eleonora Calabretta; Carmelo Carlo-Stella
Journal:  Cells       Date:  2020-03-26       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.